GlassScriptPhysician profile
Kara P Fine
NPI 1720286644
$6,095.79
in general payments reported to CMS, 2019-2025
39 companies · $626 in 2025
The $626 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $476 · 2021: $828 · 2022: $1,292 · 2023: $1,298 · 2024: $948 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,721 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,721.08 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $2,640.73 | 2019-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $568.91 | 2019-2024 | Proclaim, Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $545.79 | 2019-2023 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $316.12 | 2019-2025 | |
| Ascensia Diabetes Care US INC. | $299.43 | 2021-2025 | |
| Antares Pharma, INC. | $205.11 | 2020-2022 | |
| Amgen INC. | $163.52 | 2019-2022 | |
| Abbvie INC. | $157.30 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $127.98 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $103.28 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amneal Pharmaceuticals LLC | $97.60 | 2020-2023 | Unithroid |
| Xeris Pharmaceuticals, INC. | $96.59 | 2020-2024 | Recorlev, Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $84.76 | 2020-2023 | Strensiq |
| Horizon Therapeutics Plc | $56.44 | 2019-2023 | Tepezza |
| Medtronic, INC. | $47.21 | 2024 | Minimed 780g |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Fine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.